EGFR and lung cancer: However, some clinical studies indicated that tumors overexpressing EGFR did not show a significant clinical response to antibody-based or small molecule inhibitor therapy in lung cancer, Searching for correlates, it has been found that the presence of certain kinase domain mutations in EGFR gene appear to predict responsiveness [11-13].